Peripheral aetiopathogenic drivers and mediators of Parkinson’s disease and co-morbidities: role of gastrointestinal microbiota

Journal of NeuroVirology

Volumn 22, Issue 1, 2016, Pages 22-32

  Dobbs, Sylvia M ^a,b,c   Dobbs, R John ^a,b,c   Weller, Clive ^a   Charlett, André ^a,d   Augustin, Aisha ^a,b   Taylor, David ^a,b   Ibrahim, Mohammad A A ^a   Bjarnason, Ingvar ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Aetiology; Autoimmunity; Bystander damage; Helicobacter; Intestinal dysbiosis; Parkinson s and overlap diseases; Pathogenesis

Indexed keywords

HOMOCYSTEINE; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL OVERGROWTH; BRADYKINESIA; BYSTANDER EFFECT; CONSTIPATION; CROSS REACTION; GASTROINTESTINAL TRACT; HUMAN; HYPOKINESIA; INTESTINE FLORA; LEUKOCYTE; METABOLOME; MICROBIOME; MITOCHONDRION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RIGIDITY; SMALL INTESTINE; ANIMAL; CD4+ T LYMPHOCYTE; COGNITION DISORDERS; COMORBIDITY; DEPRESSION; DYSBIOSIS; GROWTH, DEVELOPMENT AND AGING; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; MICROBIOLOGY; NATURAL KILLER CELL; NEUTROPHIL; PATHOGENICITY; PATHOLOGY; PEPTIC ULCER;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; COGNITION DISORDERS; COMORBIDITY; DEPRESSION; DYSBIOSIS; GASTROINTESTINAL MICROBIOME; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; KILLER CELLS, NATURAL; NEUTROPHILS; PARKINSON DISEASE; PEPTIC ULCER;

EID: 84957848045     PISSN: 13550284     EISSN: 15382443     Source Type: Journal    
DOI: 10.1007/s13365-015-0357-8     Document Type: Review

References (82)

1. Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, Grandinetti A, Blanchette PL, Popper JS, Ross GW (2001) Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 57:456–462. doi:10.1212/WNL.57.3.456
2. Ahmed I, Tamouza R, Delord M, Krishnamoorthy R, Tzourio C, Mulot C, Nacfer M, Lambert JC, Beaune P, Laurent-Puig P, Loriot MA, Charron D, Elbaz A (2012) Association between Parkinson’s disease and the HLA-DRB1 locus. Mov Disord 27:1104–1110. doi:10.1002/mds.25035
3. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto J-M, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen T (2011) Enterotypes of the human gut microbiome. Nature 473:174–178. doi:10.1038/nature09944
4. Augustin A, Charlett A, Weller C, Dobbs SM, Taylor D, Ibrahim MAA, Bjarnason I, Dobbs RJ (2014) Osmotic laxatives are associated with lower rigidity in idiopathic parkinsonism. United Eur Gastroenterol J 2(suppl 1):A248
5. Bercik P, Denou E, Collins J, Jackson W, Lu J, Jury J, Deng Y, Blennerhassett P, Macri J, McCoy KD, Verdu EF, Collins SM (2011) The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology 141:599–609. doi:10.1053/j.gastro.2011.04.052
6. Berger JR, Arendt G (2000) HIV dementia: the role of the basal ganglia and dopaminergic systems. J Psychopharmacol 14:214–221. doi:10.1080/13550280290049831
7. Blottiere H, de Vos WM, Ehrlich SD, Doré J (2013) Human intestinal metagenomics: state of the art and future. Curr Opin Microbiol 16:232. doi:10.1016/j.mib.2013.06.006
8. Bodmer W (2003) RA Fisher, statistician and geneticist extraordinary: a personal view. Int J Epidemiol 32:938–942
9. Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS, Beal MF (2008) Metabolomic profiling to develop blood biomarkers for Parkinson’s disease. Brain 131:389–396. doi:10.1093/brain/awm304
10. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC (1994) Immunocytochemical analysis of tumour necrosis factor and its receptors in Parkinson’s disease. Neurosci Lett 172:151–154. doi:10.1016/0304-3940(94)90684-X
11. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211. doi:10.1016/S0197-4580(02)00065-9
12. Braak H, de Vos RA, Bohl J, Del Tredici K (2006) Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett 396:67–72. doi:10.1016/j.neulet.2005.11.012
13. Charlett A, Dobbs RJ, Weller C, Dobbs SM (1997) Stasis in the gut: the source of xenobiotic in idiopathic parkinsonism. Eur J Clin Pharmacol 52(suppl):168
14. Charlett A, Dobbs RJ, Purkiss AG, Wright DJ, Peterson DW, Weller C, Dobbs SM (1998) Cortisol is higher in parkinsonism and associated with gait deficit. Acta Neurol Scand 97:77–85. doi:10.1111/j.1600-0404.1998.tb00614.x
15. Charlett A, Dobbs RJ, Dobbs SM, Weller C, Ibrahim MA, Dew T, Sherwood R, Oxlade NL, Plant JM, Bowthorpe J, Lawson AJ, Curry A, Peterson DW, Bjarnason IT (2009) Blood profile holds clues to role of infection in a premonitory state for idiopathic parkinsonism and of gastrointestinal infection in established disease. Gut Pathogens 1:20.
16. Chen S, Le WD, Xie WJ et al (1998) Experimental destruction of substantia nigra initiated by Parkinson’s disease immunoglobulins. Arch Neurol 55:1075–1080. doi:10.1001/archneur.55.8.1075
17. Chen H, O’Reilly EJ, Schwarzschild MA, Ascherio A (2008) Peripheral inflammatory biomarkers and risk of Parkinson’s disease. Am J Epidemiol 167:90–95
18. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM (1998) Folate, vitamin B12 and serum total homocysteine levels in confirmed Alzheimer’s disease. Arch Neurol 55:1449–1455. doi:10.1001/archneur.55.11.1449
19. Collins SM, Surette M, Bercik P (2012) The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol 10:735–742. doi:10.1038/nrmicro2876
20. Cotillard A, Kennedy SP, Ling CK, Prifti E, Pons N, Le Chatelier E, Almeida M, Quinquis B, Levenez F, Galleron N, Gougis S, Rizkalla S, Batto J-M, Renault P, ANR MicroObes consortium, Doré J, Zucker J-D, Clement K, Ehrlich SD (2013) Dietary intervention impact on gut microbial gene richness. Nature 500:585–590. doi:10.1038/nature12480
21. Dahlström A, Wigander A, Lundmark K, Gottfries C-G, Carvey PM, McRae A (1990) Investigations on auto-antibodies in Alzheimer’s and Parkinson’s diseases using defined neuronal cultures. J Neural Transm 29(suppl):195–206
22. Defazio G, Dal Toso R, Benvegnù D, Minozzi MC, Cananzi AR, Leon A (1994) Parkinson serum carries complement-dependent toxicity for rat mesencephalic dopaminergic neurons in culture. Brain Res 633:206–212. doi:10.1016/0006-8993(94)91541-5
23. Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW (1999) Association of circulating TNF-α and IL-6 with ageing and parkinsonism. Acta Neurol Scand 100:34–41. doi:10.1111/j.1600-0404.1999.tb00721.x
24. Dobbs RJ, Charlett A, Dobbs SM, Weller C, Peterson DW (2000) Parkinsonism: differential age-trend in Helicobacter pylori antibody. Aliment Pharmacol Ther 14:1199–1205. doi:10.1046/j.1365-2036.2000.00815.x
25. Dobbs RJ, Dobbs SM, Weller C, Bjarnason IT, Oxlade NL, Charlett A, Al-Janabi MA, Kerwin RW, Mahler RF, Price AB (2005) Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism part 1: eradication of Helicobacter in the cachexia of idiopathic parkinsonism. Helicobacter 10:267–275. doi:10.1111/j.1523-5378.2005.00331.x
26. Dobbs RJ, Dobbs SM, Weller C, Charlett A, Bjarnason IT, Curry A, Ellis DS, Ibrahim MA, McCrossan MV, O’Donohue J, Owen RJ, Oxlade NL, Price AB, Sanderson JD, Sudhanva M, Williams J (2008) Helicobacter hypothesis for idiopathic parkinsonism: before and beyond. Helicobacter 13:309–322. doi:10.1111/j.1523-5378.2008.00622.x
27. Dobbs SM, Dobbs RJ, Weller C, Charlett A, Bjarnason IT, Lawson AJ, Letley D, Harbin L, Price AB, Ibrahim MAA, Oxlade NL, Bowthorpe J, Leckstroem D, Smee C, Plant JM, Peterson DW (2010) Differential effect of Helicobacter pylori eradication on time trends in brady/hypokinesia and rigidity in idiopathic parkinsonism. Report on completion of a randomised, double-blind, placebo-controlled efficacy study. Helicobacter 15:279–294. doi:10.1111/j.1523-5378.2010.00768.x
28. Dobbs RJ, Charlett A, Dobbs SM, Weller C, Ibrahim MAA, Iguodala O, Smee C, Plant JM, Lawson AJ, Taylor D, Bjarnason I (2012) Leukocyte-subset counts in idiopathic parkinsonism provide clues to a pathogenic pathway involving small intestinal bacterial overgrowth. A surveillance study. Gut Pathogens 4:12. doi:10.1186/1757-4749-4-12
29. Dobbs SM, Charlett A, Dobbs RJ, Weller C, Iguodala O, Smee C, Lawson AJ, Taylor D, Bjarnason I (2013) Antimicrobial surveillance in idiopathic parkinsonism: indication-specific improvement in hypokinesia following Helicobacter pylori eradication and non-specific effect of antimicrobials for other indications in worsening rigidity. Helicobacter 18:187–196. doi:10.1111/hel.12035
30. Doré J, Simrén M, Buttle L, Guarner F (2013) Hot topics in gut microbiota. United Eur Gastroenterol J 1:311–318. doi:10.1177/2050640613502477
31. Dourmashkin RR, Dunn G, Castano V, McCall SA (2012) Evidence for an enterovirus as the cause of encephalitis lethargica. BMC Infect Dis 12:136. doi:10.1186/1471-2334-12-136
32. Ehringer H, Hornykiewicz O (1960) Distribution of noradrenaline and dopamine (3-hydroxytyramine) in human brain and its relation to diseases of the extrapyramidal system. Wien Klin Wschr 38:1236–1239. doi:10.1016/S1353-8020(98)00012-1
33. Ellis D, Dobbs RJ, Dobbs S, Curry A, Bjarnason I, Williams J, McCrossan MV, Weller C, Charlett A (2007) Duodenal enterocyte mitochondrial involvement and abnormal bowel function in idiopathic parkinsonism. In: Hanin I, Windisch M, Poewe W, Fisher A (eds) ADPD 2007 new trends in Alzheimer and Parkinson related disorders. Medimond S.r.l, Bologna, pp 269–272
34. Grathwohl SA, Steiner JA, Britschgi M, Brundin P (2013) Mind the gut: secretion of α-synuclein by enteric neurons. J Neurochem 125:487–490. doi:10.1111/jnc.12191
35. Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D, Kay DM, Doheny KF, Paschall J, Pugh E, Kusel VI, Collura R, Roberts J, Griffith A, Samii A, Scott W, Nutt J, Factor SA, Payami H (2010) Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease. Nat Genet 42:781–785. doi:10.1038/ng.642
36. He Y, Le W-D, Appel SH (2002) Role of Fcγ receptors in nigral cell injury induced by Parkinson disease immunoglobulin injection into mouse substantia nigra. Exp Neurol 176:322–327. doi:10.1006/exnr.2002.7946
37. Hill AB (1965) The environment and disease: association or causation? Proc R Soc Med 58:295–330
38. Hunot S, Brugg B, Ricard D, Michel PP, Muriel M-P, Ruberg M, Faucheux BA, Agid Y, Hirsch EC (1997) Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson’s disease. Proc Natl Acad Sci U S A 94:7531–7536. doi:10.1073/pnas.94.14.7531
39. International Parkinson Disease Genetics Consortium, Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, Saad M, Simón-Sánchez J, Schulte C, Lesage S, Sveinbjörnsdóttir S, Stefánsson K, Martinez M, Hardy J, Heutink P, Brice A, Gasser T, Singleton AB, Wood NW (2011) Imputation of sequence variants for identification of genetic risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet 377:641–649. doi:10.1016/S0140-6736(10)62345-8
40. Karlsen NR, Reinvang I, Frøland SS (1992) Slowed reaction time in asymptomatic HIV-positive patients. Acta Neurol Scand 86:242–246. doi:10.1111/j.1600-0404.1992.tb05078.x
41. Kirollos C, O.’Neill CJA, Dobbs RJ, Charlett A, Bowes SG, Purkiss AG, Hunt WB, Dobbs SM (1993) Quantification of the cardinal signs of parkinsonism and of associated disability in spouses of sufferers. Age Ageing 22:20–26. doi:10.1093/ageing/22.1.20
42. Kirollos C, Charlett A, O’Neill CJA, Kosik R, Mozol K, Purkiss AG, Bowes SG, Nicholson PW, Hunt WB, Weller C, Dobbs SM, Dobbs RJ (1996) Objective measurement of activation of rigidity: diagnostic, pathogenetic and therapeutic implications in parkinsonism. Br J Clin Pharmacol 41:557–564. doi:10.1046/j.1365-2125.1996.38313.x
43. Kok B, Foxton MR, Clough C, Shawcross DL (2013) Rifaximin is an efficacious treatment for the parkinsonian phenotype of hepatic encephalopathy. Hepatology 58:1516–1517. doi:10.1002/hep.26364
44. Kordower JH, Chu Y, Hauser RA, Olanow CW, Freeman TB (2008) Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord 23:2303–2306. doi:10.1002/mds.22369
45. Koutsilieri E, Sopper S, Scheller C, ter Meulen V, Reiderer P (2002) Parkinsonism in HIV dementia. J Neural Transm 109:767–775. doi:10.1007/s007020200063
46. Kuhn TS (1970) The structure of scientific revolutions, 2nd edn. The University of Chicago Press, Chicago, Enlarged
47. Lazzerini PE, Capecchi PL, Selvi E, Lorenzini S, Bisogno S, Galeazzi M, Pasini FL (2007) Hyperhomocysteinemia, inflammation and autoimmunity. Autoimmun Rev 6:503–509. doi:10.1016/j.autrev.2007.03.008
48. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto J-M, Kennedy S, Leonard P, Li J, Burgdorf K, Grarup N, Jørgensen T, Brandslund I, Nielsen HB, Juncker AS, Bertalan M, Levenez F, Pons N, Rasmussen S, Sunagawa S, Tap J, Tims S (2013) Richness of human gut microbiome correlates with metabolic markers. Nature 500:541–546. doi:10.1038/nature12506
49. Lewin PK, Edwards V (1991) Mitochondrial inclusions in neurons of Creutzfeldt-Jakob-like disease. Lancet 337:236–237. doi:10.1016/0140-6736(91)92199-C
50. Luk KC, Song C, O’Brien P, Stieber A, Branch JR, Brunden KR, Trojanowski JQ, Lee VM (2009) Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A 106:20051–20056. doi:10.1073%2Fpnas.0908005106
51. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C, Chardon P, Marteau P, Roca J, Dore J (2006) Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut 55:205–211. doi:10.1136/gut.2005.073817
52. Marshall BJ, Warren JR (1984) Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet i:1311–1315. doi:10.1016/SO140-6736(84)91816-6
53. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1998) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38:1285–1289. doi:10.1212/WNL.38.8.1285
54. McRae A, Degueurce A, Gottfries C-G, Karlsson I, Svennerholm L, Dahlström A (1986) Antibodies in the CSF of a Parkinson patient recognizes neurons in rat mesencephalic regions. Acta Physiol Scand 126:313–315. doi:10.1111/j.1748-1716.1986.tb07821
55. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T (1994) Interleukin-1-beta, interleukin-6, epidermal growth-factor-alpha and transforming growth-factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 180:147–150. doi:10.1016/0304-3940(94)90508-8
56. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T (1996) Interleukin (IL)-1-beta, IL-2, IL-4, Il-6 and transforming growth-factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson’s disease. Neurosci Lett 211:13–16. doi:10.1016/0304-3940(96)12706-3
57. Nakhleh MK, Badarny S, Winer R, Jeries R, Finberg J, Haick H (2015) Distinguishing idiopathic Parkinson’s disease from other parkinsonian syndromes by breath test. Parkinsonism Relat Disord 21:150–153. doi:10.1016/j.parkreldis.2014.11.023
58. Neish AS (2009) Microbes in gastrointestinal health and disease. Gastroenterology 136:65–80. doi:10.1053/j.gastro.2008.10.080
59. Nielsen HH, Qiu J, Friis S, Wermuth L, Ritz B (2012) Treatment for Helicobacter pylori infection and risk of Parkinson’s disease in Denmark. Eur J Neurol 19:864–869. doi:10.1111/j.1468-1331.2011.03643.x
60. OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx/o=5653
61. O’Neill CJA, Richardson MD, Charlett A, McHugh L, Bowes SG, Purkiss AG, Weller C, Dobbs SM, Dobbs RJ (1994) Could seborrhoeic dermatitis be implicated in the pathogenesis of parkinsonism? Acta Neurol Scand 89:252–257. doi:10.1111/j.1600-0404.1994.tb01675.x
62. Orešič M, Hyötyläinen T, Herukka S-K, Sysi-Aho M, Mattila I, Seppänan-Laakso T, Julkunen V, Gopalacharyulu PV, Hallikainen M, Koikkalainen J, Kivipelto M, Helisalmi S, Lötjönen J, Soininen H (2011) Metabolome in progression to Alzheimer’s disease. Transl Psychiatry 1, e57. doi:10.1038/tp.2011.55
63. Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM (2005) A possible role for humoral immunity in the pathogenesis of Parkinson’s disease. Brain 28:2665–2674. doi:10.1093/brain/awh625
64. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T (2005) Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol 2005(57):168–175. doi:10.1002/ana.20338
65. Ouchi Y, Yagi S, Yokokura M, Sakamoto M (2009) Neuroinflammation in the living brain of Parkinson’s disease. Parkinsonism Relat Disord 15(S3):S200–S204. doi:10.1016/S1353-8020(09)70814-4
66. Parkinson J (1817) An essay on the shaking palsy. Sherwood, Neely and Jones, London
67. Pfeiffer RF (2009) Neuroinflammation and Parkinson disease: the silent battleground. Neurology 73:1434–1435. doi:10.1212/WNL.0b013e3181c2f07d
68. Phillips RJ, Walter GC, Wilder SL, Baronowsky EA, Powley TL (2008) Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson’s disease? Neuroscience 153:733–750. doi:10.1016/j.neuroscience.2008.02.074
69. Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. Science 216:136–144. doi:10.1126/science.6801762
70. Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, Guo J, Le Chatelier E, Yao J, Wu L, Zhou J, Ni S, Liu L, Pons N, Batto JM, Kennedy SP, Leonard P, Yuan C, Ding W, Chen Y, Hu X, Zheng B, Qian G, Xu W, Ehrlich SD, Zheng S, Li L (2014) Alterations of the human gut microbiome in liver cirrhosis. Nature 513:59–64. doi:10.1038/nature13568
71. Reale M, Iarlori C, Thomas A, Gambi D, Perfetti B, Nicola MD, Onofrj M (2009) Peripheral cytokines profile in Parkinson’s disease. Brain Behav Immun 23:55–63. doi:10.1016/j.bbi.2008.07.003
72. Refsum H, Smith AD (2003) Low vitamin B-12 status in confirmed Alzheimer’s disease as revealed by serum holotranscobalamin. J Neurol Neurosurg Psychiatry 74:959–961. doi:10.1136/jnnp.74.7.959
73. Scheperjans F, Aho V, Pereira PAB, Koskinen K, Paulin L, Pekkonen E, Haapaniemi E, Kaakkola S, Eerola-Rautio J, Pohja M, Kinnunen E, Murros K, Auvinen P (2014) Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov Disord. doi:10.1002/mds.26069
74. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D’Agostino RB, Wilson PWF, Wolf PA (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med 346:476–483. doi:10.1056/NEJMoa011613
75. Sikiric P, Rotkvic I, Mise S, Petek M, Rucman R, Seiwerth S, Zjacic-Rotkvic V, Duvnjak M, Jagic V, Suchanek E, Grabarevic Z, Tomislav A, Brkic T, Djermanovic Z, Dodig M, Marovic A, Hernandez DE (1991) Dopamine agonists prevent duodenal ulcer relapse. Dig Dis Sci 36:905–910
76. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, Glickman JN, Garrett WS (2013) The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341:569–573. doi:10.1126/science.1241165
77. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, Lango Allen H, Lindgren CM, Luan J, Mägi R, Randall JC, Vedantam S, Winkler TW, Qi L, Workalemahu T, Heid IM, Steinthorsdottir V, Stringham HM, Weedon MN, Wheeler E, Wood AR, Ferreira T, Weyant RJ, Segrè AV, Estrada K, Liang L, Nemesh J, Park JH, Gustafsson S, Kilpeläinen TO, Yang J, Bouatia-Naji N, Esko T, Feitosa MF, Kutalik Z, Mangino M, Raychaudhuri S, Scherag A, Smith AV, Welch R, Zhao JH, Aben KK, Absher DM, Amin N, Dixon AL, Fisher E, Glazer NL, Goddard ME, Heard-Costa NL, Hoesel V, Hottenga JJ, Johansson A, Johnson T, Ketkar S, Lamina C, Li S, Moffatt MF, Myers RH, Narisu N, Perry JR, Peters MJ, Preuss M, Ripatti S, Rivadeneira F, Sandholt C, Scott LJ, Timpson NJ, Tyrer JP, van Wingerden S, Watanabe RM, White CC, Wiklund F, Barlassina C, Chasman DI, Cooper MN, Jansson JO, Lawrence RW, Pellikka N, Prokopenko I, Shi J, Thiering E, Alavere H, Alibrandi MT, Almgren P, Arnold AM, Aspelund T, Atwood LD, Balkau B, Balmforth AJ, Bennett AJ, Ben-Shlomo Y, Bergman RN, Bergmann S, Biebermann H, Blakemore AI, Boes T, Bonnycastle LL, Bornstein SR, Brown MJ, Buchanan TA, Busonero F, Campbell H, Cappuccio FP, Cavalcanti-Proença C, Chen YD, Chen CM, Chines PS, Clarke R, Coin L, Connell J, Day IN, den Heijer M, Duan J, Ebrahim S, Elliott P, Elosua R, Eiriksdottir G, Erdos MR, Eriksson JG, Facheris MF, Felix SB, Fischer-Posovszky P, Folsom AR, Friedrich N, Freimer NB, Fu M, Gaget S, Gejman PV, Geus EJ, Gieger C, Gjesing AP, Goel A, Goyette P, Grallert H, Grässler J, Greenawalt DM, Groves CJ, Gudnason V, Guiducci C, Hartikainen AL, Hassanali N, Hall AS, Havulinna AS, Hayward C, Heath AC, Hengstenberg C, Hicks AA, Hinney A, Hofman A, Homuth G, Hui J, Igl W, Iribarren C, Isomaa B, Jacobs KB, Jarick I, Jewell E, John U, Jørgensen T, Jousilahti P, Jula A, Kaakinen M, Kajantie E, Kaplan LM, Kathiresan S, Kettunen J, Kinnunen L, Knowles JW, Kolcic I, König IR, Koskinen S, Kovacs P, Kuusisto J, Kraft P, Kvaløy K, Laitinen J, Lantieri O, Lanzani C, Launer LJ, Lecoeur C, Lehtimäki T, Lettre G, Liu J, Lokki ML, Lorentzon M, Luben RN, Ludwig B, MAGIC, Manunta P, Marek D, Marre M, Martin NG, McArdle WL, McCarthy A, McKnight B, Meitinger T, Melander O, Meyre D, Midthjell K, Montgomery GW, Morken MA, Morris AP, Mulic R, Ngwa JS, Nelis M, Neville MJ, Nyholt DR, O’Donnell CJ, O’Rahilly S, Ong KK, Oostra B, Paré G, Parker AN, Perola M, Pichler I, Pietiläinen KH, Platou CG, Polasek O, Pouta A, Rafelt S, Raitakari O, Rayner NW, Ridderstråle M, Rief W, Ruokonen A, Robertson NR, Rzehak P, Salomaa V, Sanders AR, Sandhu MS, Sanna S, Saramies J, Savolainen MJ, Scherag S, Schipf S, Schreiber S, Schunkert H, Silander K, Sinisalo J, Siscovick DS, Smit JH, Soranzo N, Sovio U, Stephens J, Surakka I, Swift AJ, Tammesoo ML, Tardif JC, Teder-Laving M, Teslovich TM, Thompson JR, Thomson B, Tönjes A, Tuomi T, van Meurs JB, van Ommen GJ, Vatin V, Viikari J, Visvikis-Siest S, Vitart V, Vogel CI, Voight BF, Waite LL, Wallaschofski H, Walters GB, Widen E, Wiegand S, Wild SH, Willemsen G, Witte DR, Witteman JC, Xu J, Zhang Q, Zgaga L, Ziegler A, Zitting P, Beilby JP, Farooqi IS, Hebebrand J, Huikuri HV, James AL, Kähönen M, Levinson DF, Macciardi F, Nieminen MS, Ohlsson C, Palmer LJ, Ridker PM, Stumvoll M, Beckmann JS, Boeing H, Boerwinkle E, Boomsma DI, Caulfield MJ, Chanock SJ, Collins FS, Cupples LA, Smith GD, Erdmann J, Froguel P, Grönberg H, Gyllensten U, Hall P, Hansen T, Harris TB, Hattersley AT, Hayes RB, Heinrich J, Hu FB, Hveem K, Illig T, Jarvelin MR, Kaprio J, Karpe F, Khaw KT, Kiemeney LA, Krude H, Laakso M, Lawlor DA, Metspalu A, Munroe PB, Ouwehand WH, Pedersen O, Penninx BW, Peters A, Pramstaller PP, Quertermous T, Reinehr T, Rissanen A, Rudan I, Samani NJ, Schwarz PE, Shuldiner AR, Spector TD, Tuomilehto J, Uda M, Uitterlinden A, Valle TT, Wabitsch M, Waeber G, Wareham NJ, Watkins H, Procardis C, Wilson JF, Wright AF, Zillikens MC, Chatterjee N, McCarroll SA, Purcell S, Schadt EE, Visscher PM, Assimes TL, Borecki IB, Deloukas P, Fox CS, Groop LC, Haritunians T, Hunter DJ, Kaplan RC, Mohlke KL, O’Connell JR, Peltonen L, Schlessinger D, Strachan DP, van Duijn CM, Wichmann HE, Frayling TM, Thorsteinsdottir U, Abecasis GR, Barroso I, Boehnke M, Stefansson K, North KE, McCarthy MI, Hirschhorn JN, Ingelsson E, Loos RJ (2010) Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 42:937–948. doi:10.1038/ng.686
78. Strang RR (1965) The association of gastro-duodenal ulceration with Parkinson’s disease. Med J Aust 52:842–843
79. Vonka V (2000) Causality in medicine: the case of tumours and viruses. Philos Trans R Soc Lond B 335:1831–1841. doi:10.1098/rstb.2000.0738
80. Watkins AD (1995) Perceptions, emotions and immunity: an integrated homeostatic network. Q J Med 88:283–294. doi:10.1016/S1443-8461(02)80004-1
81. Weller C, Nicholson PW, Dobbs SM, Bowes SG, Purkiss A, Dobbs RJ (1992) Reduced axial rotation in the spouses of sufferers from idiopathic Parkinsonism. Age Ageing 21:189–194. doi:10.1093/ageing/21.3.189
82. Weller C, Oxlade NL, Dobbs SM, Dobbs RJ, Peterson DW, Bjarnason IT (2005) Role of chronic infection and inflammation in the gastrointestinal tract in the aetiology and pathogenesis of idiopathic parkinsonism. Part 3: predicted probability and gradients of severity of idiopathic parkinsonism based on H. pylori antibody profile. Helicobacter 10:288–297. doi:10.1111/j.1523-5378.2005.00329